Open Access

Correlation of treatment outcome in sanger/RT‑qPCR KIT/PDGFRA wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report

  • Authors:
    • Mojca Unk
    • Alenka Bombač
    • Barbara Jezeršek Novaković
    • Vida Stegel
    • Vita Šetrajčič Dragoš
    • Olga Blatnik
    • Gašper Klančar
    • Srdjan Novaković
  • View Affiliations

  • Published online on: July 28, 2022     https://doi.org/10.3892/or.2022.8382
  • Article Number: 167
  • Copyright: © Unk et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In patients with gastrointestinal stromal tumors (GIST), it has become mandatory to determine the driver mutation in order to predict the response to standard treatment with tyrosine kinase inhibitors (TKI). A total of 10‑15% of all GIST lack activating mutations in KIT proto‑oncogene, receptor tyrosine kinase (KIT)/platelet‑derived growth factor receptor alpha (PDGFRA) and have been classified as KIT/PDGFRA wild‑type (WT) GIST. They are characterized by poor response to TKI. From a group of 119 metastatic GIST patients, 17 patients with KIT/PDGFRA/BRAF WT GIST as determined by reverse transcription‑quantitative (RT‑q) PCR and Sanger sequencing were profiled by a targeted next‑generation sequencing (NGS) approach and their treatment outcome was assessed. In the present study, 41.2% of patients as KIT/PDGFRA/BRAF WT GIST examined with RT‑qPCR and Sanger sequencing were confirmed to be carriers of pathogenic KIT/PDGFRA mutations by NGS and were responsive to TKI. The percentage of genuinely KIT/PDGFRA WT GIST in the present study thereby dropped from the initial 14.3% detected with the RT‑qPCR and Sanger sequencing to 7.6% after NGS. Their outcome was universally poor. The reliability of RT‑qPCR and direct Sanger sequencing results in this setting is therefore insufficient and it is recommended that NGS becomes a requirement for treatment decision at least in KIT/PDGFRA/BRAF WT GIST as determined by RT‑qPCR and Sanger sequencing.

Related Articles

Journal Cover

September-2022
Volume 48 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Unk M, Bombač A, Jezeršek Novaković B, Stegel V, Šetrajčič Dragoš V, Blatnik O, Klančar G and Novaković S: Correlation of treatment outcome in sanger/RT‑qPCR <em>KIT/PDGFRA</em> wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report. Oncol Rep 48: 167, 2022
APA
Unk, M., Bombač, A., Jezeršek Novaković, B., Stegel, V., Šetrajčič Dragoš, V., Blatnik, O. ... Novaković, S. (2022). Correlation of treatment outcome in sanger/RT‑qPCR <em>KIT/PDGFRA</em> wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report. Oncology Reports, 48, 167. https://doi.org/10.3892/or.2022.8382
MLA
Unk, M., Bombač, A., Jezeršek Novaković, B., Stegel, V., Šetrajčič Dragoš, V., Blatnik, O., Klančar, G., Novaković, S."Correlation of treatment outcome in sanger/RT‑qPCR <em>KIT/PDGFRA</em> wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report". Oncology Reports 48.3 (2022): 167.
Chicago
Unk, M., Bombač, A., Jezeršek Novaković, B., Stegel, V., Šetrajčič Dragoš, V., Blatnik, O., Klančar, G., Novaković, S."Correlation of treatment outcome in sanger/RT‑qPCR <em>KIT/PDGFRA</em> wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report". Oncology Reports 48, no. 3 (2022): 167. https://doi.org/10.3892/or.2022.8382